scholarly journals Consumptive Coagulopathy and Thrombosis during Severe COVID-19 Infection: Potential Involvement of VWF/ADAMTS13

2020 ◽  
Author(s):  
Upendra K. Katneni ◽  
Aikaterini Alexaki ◽  
Ryan Hunt ◽  
Tal Schiller ◽  
Michael DiCuccio ◽  
...  
Keyword(s):  
World Health ◽  
Clinical Prognosis ◽  
Antithrombotic Activity ◽  
Inflammatory Conditions ◽  
Early Evidence ◽  
The World ◽  
Health Organization ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Reduced Activity

Coronavirus disease of 2019 (COVID-19) is the clinical manifestation of the respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Following its origin as a regional outbreak in Wuhan, China, COVID-19 rapidly spread globally and eventually was designated as pandemic by the World Health Organization. Multiple studies describing the clinical characteristics of COVID-19 patients highlighted the prevalence of abnormal coagulopathy and higher incidence of thrombosis. These studies identified co-morbid inflammatory disorders as risk factors for hospitalization in SARS-CoV-2 infections. While early evidence suggested inflammatory conditions as the leading cause of abnormal coagulopathy in COVID-19 patients, the mechanisms behind progression of inflammation mediated hemostasis dysregulation to thrombotic outcomes in susceptible individuals are not well understood. In addition, a sensitive and temporal assessments of coagulation and fibrinolysis is still lacking. Von Willebrand Factor (VWF) and ADAMTS13 interactions play an important role in the maintenance of hemostasis and prevention of unwanted thrombosis. In inflammatory conditions, VWF-ADAMTS13 imbalance characterized by elevated VWF levels and inhibited and/or reduced activity of ADAMTS13 is reported. Also, an imbalance between ADAMTS13 activity and VWF antigen is associated with organ dysfunction and death in patients with systemic inflammation. Despite the natural antithrombotic activity of ADAMTS13, its role in COVID-19 pathophysiology, specifically thrombotic outcomes has not yet been investigated. A thorough understanding of VWF-ADAMTS13 interactions during early and advanced phases of COVID-19 could help define the pathophysiology, guide thromboprophylaxis and treatment and improve clinical prognosis.

scholarly journals Description Of Depression Rates In Drug Case Inmates In Class II A Bulukumba Correctional Institution

2021 ◽  
Vol 5 (1) ◽  
pp. 26-31
Author(s):  
Magfirah Ichlasul Amalia ◽  
Nurlina ◽  
Safruddin
Keyword(s):  
World Health Organization ◽  
Class Ii ◽  
World Health ◽  
Common Disease ◽  
Correctional Institution ◽  
Mild Depression ◽  
The World ◽  
Depression Disorders ◽  
Health Organization ◽  
Reduced Activity

Depression is an affective disorder, which is generally characterized by loss of interest or excitement, reduced energy so that it is easily tired and reduced activity. Depression can occur in anyone and at any period. Depression disorders have increased from year to year this is supported by data, the World Health Organization WHO which states depression is a common disease that occurs in the world, there are about 264 million people who suffer from depression that increases from year to year about 76-85%. The goal is to identify the level of depression in drug inmates in The Correctional Institution Class II A Bulukumba Method used in this study is a descriptive design, which aims to get an overview of the level of depression in drug case inmates in The Correctional Institution Class II A Bulukumba. The affordable population in this study was inmates with drug cases, as many as 141 drug case inmates in the correctional institution Kls II A Bulukumba. The large sample in this study was 85 people. The researchers found results from 85 respondents (100%) obtained results for the highest depressed proposri is mild depression with the number of 55 (64.7%), while the lowest respondents who do not megalami depression with the number of 14 (16.5%). The conclusion of this study is that there is a picture of the level of depression of drug case inmates in the correctional institution class II A Bulukumba. And researchers suggest that the results of this study can be used as a material to increase insights in the field of research as well as increase knowledge about depression and drug cases at the Correctional Institution Class II A Bulukumba.

scholarly journals Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus

2020 ◽  
Vol 120 (12) ◽  
pp. 1668-1679 ◽  
Author(s):  
Upendra K. Katneni ◽  
Aikaterini Alexaki ◽  
Ryan C. Hunt ◽  
Tal Schiller ◽  
Michael DiCuccio ◽  
...  
Keyword(s):  
Fungal Infections ◽  
Multiple Organ ◽  
Coagulation System ◽  
Clinical Feature ◽  
Clinical Prognosis ◽  
Inflammatory Conditions ◽  
Organ Systems ◽  
A Disintegrin And Metalloproteinase ◽  
Von Willebrand ◽  
Willebrand Factor

AbstractCoronavirus disease of 2019 (COVID-19) is the clinical manifestation of the respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While primarily recognized as a respiratory disease, it is clear that COVID-19 is systemic illness impacting multiple organ systems. One defining clinical feature of COVID-19 has been the high incidence of thrombotic events. The underlying processes and risk factors for the occurrence of thrombotic events in COVID-19 remain inadequately understood. While severe bacterial, viral, or fungal infections are well recognized to activate the coagulation system, COVID-19-associated coagulopathy is likely to have unique mechanistic features. Inflammatory-driven processes are likely primary drivers of coagulopathy in COVID-19, but the exact mechanisms linking inflammation to dysregulated hemostasis and thrombosis are yet to be delineated. Cumulative findings of microvascular thrombosis has raised question if the endothelium and microvasculature should be a point of investigative focus. von Willebrand factor (VWF) and its protease, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS-13), play important role in the maintenance of microvascular hemostasis. In inflammatory conditions, imbalanced VWF-ADAMTS-13 characterized by elevated VWF levels and inhibited and/or reduced activity of ADAMTS-13 has been reported. Also, an imbalance between ADAMTS-13 activity and VWF antigen is associated with organ dysfunction and death in patients with systemic inflammation. A thorough understanding of VWF-ADAMTS-13 interactions during early and advanced phases of COVID-19 could help better define the pathophysiology, guide thromboprophylaxis and treatment, and improve clinical prognosis.

scholarly journals Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus

2020 ◽  
Author(s):  
Upendra K. Katneni ◽  
Aikaterini Alexaki ◽  
Ryan C. Hunt ◽  
Tal Schiller ◽  
Michael DiCuccio ◽  
...  
Keyword(s):  
Fungal Infections ◽  
Multiple Organ ◽  
Coagulation System ◽  
Clinical Feature ◽  
Clinical Prognosis ◽  
Inflammatory Conditions ◽  
Organ Systems ◽  
Von Willebrand ◽  
Underlying Processes ◽  
Willebrand Factor

Coronavirus disease of 2019 (COVID-19) is the clinical manifestation of the respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While primarily recognized as a respiratory disease, it is clear that COVID-19 is systemic illness impacting multiple organ systems. One defining clinical feature of COVID-19 has been the high incidence of thrombotic events. The underlying processes and risk factors for the occurrence of thrombotic events in COVID-19 remain inadequately understood. While severe bacterial, viral or fungal infections are well recognized to activate the coagulation system, COVID-19 associated coagulopathy is likely to have unique mechanistic features. Inflammatory-driven processes are likely primary drivers of coagulopathy in COVID-19, but the exact mechanisms linking inflammation to dysregulated hemostasis and thrombosis are yet to be delineated. Cumulative findings of microvascular thrombosis has raised question if the endothelium and microvasculature should be a point of investigative focus. Von Willebrand Factor (VWF) and its protease, ADAMTS13 play important role in the maintenance of microvascular hemostasis. In inflammatory conditions, imbalanced VWF-ADAMTS13 characterized by elevated VWF levels and inhibited and/or reduced activity of ADAMTS13 has been reported. Also, an imbalance between ADAMTS13 activity and VWF antigen is associated with organ dysfunction and death in patients with systemic inflammation. A thorough understanding of VWF-ADAMTS13 interactions during early and advanced phases of COVID-19 could help better define the pathophysiology, guide thromboprophylaxis and treatment and improve clinical prognosis.

scholarly journals Managing patients with endocrine dysfunction during COVID-19: Review of literatures

2020 ◽  
Vol 8 (S1) ◽  
pp. 90-98
Author(s):  
Patro PM ◽  
Rao KVJ
Keyword(s):  
Adrenal Insufficiency ◽  
World Health ◽  
Oral Steroid ◽  
Severe Illness ◽  
Diabetic Patients ◽  
Inflammatory Conditions ◽  
The World ◽  
Bowel Diseases ◽  
Health Organization

Coronavirus disease (COVID-19), caused by the severe acute respiratory distress syndrome. Coronavirus 2 (SARS-CoV-2) is labeled as a global pandemic by the World Health Organization (WHO) on 12th March 2020, is sweeping across the world. There has been documented evidence from China that those patients who have endocrinological disorders face additional risks from COVID-19. Healthcare professionals consider people with diabetes are at higher risk of severe illness. As such people with diabetes are not more likely to get COVID-19 than the general population, but they experience severe symptoms, complications and worse outcome even death, once infected. Hence specific measures are advised for the diabetic patients. The same goes for people with autoimmune conditions that lead to adrenal insufficiency. There may be primary (Addison’s disease), secondary or tertiary adrenal insufficiency in some patients. They regulate the blood pressure, the immune response and body’s stress response. However, nearly 5% of the population takes long-term steroids for inflammatory conditions like bronchial asthma, inflammatory bowel diseases etc.; out of which many would have some degree of insufficient adrenal response in a crisis. As it relates to COVID-19, any such patient who has been on long term corticosteroid therapy; with a dry continuous cough, breathing difficulty and fever should immediately double their daily oral steroid dose and continue this regimen until the fever has subsided. It is recommended for people with adrenal insufficiency. Apart from that, they should seek immediate medical help to avoid complications. Keywords: COVID-19; diabetes; endocrinological disorders; SARS-CoV-2

Erstes Instrument zur standardisierten Erfassung der Teilhabe Behinderter

2017 ◽  
Vol 79 (07) ◽  
pp. 526-527
Keyword(s):  
World Health Organization ◽  
World Health ◽  
The World ◽  
Health Organization ◽  
Menschen Mit Behinderung

Coenen M et al. [Recommendation for the collection and analysis of data on participation and disability from the perspective of the World Health Organization]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2016; 59: 1060–1067 Um eine gleichberechtigte Teilhabe an der Gesellschaft von Menschen mit Behinderung zu ermöglichen, werden zunächst Daten zu vorhandenen Einschränkungen gebraucht. Erst wenn diese detailliert erhoben wurden, können Konzepte zur Beseitigung von Problemen entwickelt werden. Ein standardisiertes Erhebungsinstrument für alle Aspekte der Funktionsfähigkeit fehlte jedoch bisher.

Coronavirus diseases and pregnancy: COVID-19,SARS, and MERS

2020 ◽  
pp. 276-289
Author(s):  
Mobina Fathi ◽  
Kimia Vakili ◽  
Niloofar Deravi
Keyword(s):  
Pregnant Women ◽  
Intrauterine Growth Retardation ◽  
Negative Impact ◽  
World Health ◽  
Wuhan City ◽  
Intrauterine Growth ◽  
Exponential Increase ◽  
The World ◽  
Health Organization ◽  
Respiratory Droplets

Around the end of December 2019, a new beta-coronavirus from Wuhan City, Hubei Province, China began to spread rapidly. The new virus, called SARS-CoV-2, which could be transmitted through respiratory droplets, had a range of mild to severe symptoms, from simple cold in some cases to death in others. The disease caused by SARS-CoV-2 was named COVID-19 by WHO and has so far killed more people than SARS and MERS. Following the widespread global outbreak of COVID-19, with more than 132758 confirmed cases and 4955 deaths worldwide, the World Health Organization declared COVID-19 a pandemic disease in January 2020. Earlier studies on viral pneumonia epidemics has shown that pregnant women are at greater risk than others. During pregnancy, the pregnant woman is more prone to infectious diseases. Research on both SARS-CoV and MERS-CoV, which are pathologically similar to SARS-CoV-2, has shown that being infected with these viruses during pregnancy increases the risk of maternal death, stillbirth, intrauterine growth retardation and, preterm delivery. With the exponential increase in cases of COVID-19 throughout the world, there is a need to understand the effects of SARS-CoV-2 on the health of pregnant women, through extrapolation of earlier studies that have been conducted on pregnant women infected with SARS-CoV, and MERS-CoV. There is an urgent need to understand the chance of vertical transmission of SARS-CoV-2 from mother to fetus and the possibility of the virus crossing the placental barrier. Additionally, since some viral diseases and antiviral drugs may have a negative impact on the mother and fetus, in which case, pregnant women need special attention for the prevention, diagnosis, and treatment of COVID-19.

Sign in / Sign up

Export Citation Format

Share Document